Age-descending safety and immune response of a cholera conjugate vaccine in people aged 1–45

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a randomized, controlled, phase II safety and immunogenicity trial enrolling about 390 participants across three age cohorts (18–45, 5–17, and 1–4 years) using an age-descending design. Adults and older children will be enrolled in observer-blind, placebo-controlled arms comparing single versus two 25 μg doses of OSP:rTTHc CCV with or without aluminum phosphate; the youngest cohort will be randomized with active control and partial open-label elements. Doses are given six months apart where two-dose schedules are used, and an independent DSMB must clear safety before enrolling the next younger cohort. The trial includes comparator arms with licensed oral cholera vaccine (Euvichol®-Plus) and placebo to guide optimal formulation and dosing for endemic settings.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Individuals aged 1 to 45 years at consent
2. Participants/ Participants' legally authorized representative (LAR) willing to provide written informed consent to participate in the study voluntarily
3. Participants who can comply with the study requirements
4. Individuals in good health as determined by the outcome of medical history, physical examination, and the clinical judgment of the investigator

Exclusion Criteria:

1. Known history or allergy to investigational vaccine components or other medications, or any other allergies
2. Individuals with major congenital abnormalities
3. Known history of immune function disorders including immunodeficiency diseases (known HIV infection¥ or other immune function disorders)
4. Use of systemic steroids within past 6 months (\>10 mg/day prednisone equivalent for periods exceeding 2 consecutive weeks), or receive chemotherapy, radiation therapy or other immunosuppressive drugs within the past 6 months.
5. Any abnormality or chronic disease which in the opinion of the investigator might be detrimental for the safety of the participant and interfere with the assessment of the study objectives
6. Individuals with behavioral or cognitive impairment or psychiatric disease or neural disorders that, in the opinion of the investigator, could interfere with the participant's ability to participate in the trial
7. Individuals with splenectomy
8. Individuals with known bleeding disorders
9. Receipt of blood, blood-derived products, or immunoglobulin products in the past 3 months
10. Individuals who have received other vaccines from 4 weeks prior to the first dose of test vaccination or planned to receive any vaccine within 4 weeks of the last dose of the investigational product.
11. Individuals with active or known previous Vibrio cholerae infection
12. Individuals with a history of severe diarrhea in the last 6 months requiring care at a medical facility lasting 24 hours or more
13. Individuals with prior receipt of a cholera vaccine in the last 5 years
14. Any female participant who is lactating or pregnant
15. Females of childbearing potential who do not agree to use an effective birth control method for at least 4 weeks before the screening and up to 12 weeks after the study vaccination.
16. Individuals enrolled in another clinical trial within 6 months prior to enrollment, concomitantly enrolled or scheduled to be enrolled in another trial during study period
17. Individuals who are research staff involved with the clinical trial or family/household members of research staff
18. As per Investigator's medical judgement, an individual could also be excluded from the study despite meeting all inclusion/exclusion criteria mentioned above
19. Children below 5 years old with Weight for Height Z score and/or Height for Age Z score of less than -2

Where it's running

• KAVI-Institute of Clinical Research, University
  Nairobi, Kenyatta National Hospital Complex, Kenya Recruiting

Study contacts

• Principal investigator: Julia Lynch, MD — International Vaccine Institute
• Study coordinator: Naveena D'Cor, MD
• Email: naveena.dcor@ivi.int
• Phone: +82 2 8811 000

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Extended dosing schedules for the oral cholera vaccine in Kenya

  This tests whether giving the Euvichol-S oral cholera vaccine with longer gaps between doses (2 months or 12 months instead of the standard 2 weeks) produces a similar immune response in people aged 1 year and older in Mukuru, Nairobi.

  Recruiting Phase 4 Albert B. Sabin Vaccine Institute · Nairobi · NCT07487077

• Compare Biovac OCV-S and Euvichol‑Plus for immunogenicity, safety, and lot consistency

  This research will test whether the oral vaccine Biovac OCV‑S works as well and is as safe as Euvichol‑Plus for children, healthy adults, and adults living with HIV.

  Recruiting at 2 sites Phase 3 International Vaccine Institute · Durban, Eastern Cape and 4 other locations · NCT07304284

• PanChol vaccine safety study in healthy adults

  This study tests whether the PanChol oral cholera vaccine is safe and what kind of immune response it provokes in healthy adults aged 18 to 55.

  Recruiting Phase 1 Centre for Infectious Disease Research in Zambia · Lusaka, Lusaka Province · NCT07107516

• Understanding immune responses to typhoid and cholera vaccines

  This study is testing how the typhoid and cholera vaccines affect the immune system and gut bacteria in people who are having endoscopies.

  Recruiting Phase 4 University of Maryland, Baltimore · Baltimore, Maryland · NCT03705585

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.